

Reactive and Bioactive Cationic α -Helical Polypeptide Template for Nonviral Gene Delivery**

Nathan P. Gabrielson, Hua Lu, Lichen Yin, Dong Li, Fei Wang,* and Jianjun Cheng*

Polypeptides were the first set of materials considered for use as nonviral gene delivery vectors. With its ability to bind and condense anionic plasmid DNA, cationic poly-L-lysine (PLL) was one of the most well studied of the early gene delivery polypeptides.^[1,2] Unfortunately, as a DNA delivery vector, unmodified PLL suffered from low transfection efficiency. Although there have been tremendous efforts to increase the efficiency of PLL-mediated gene delivery by incorporating various motifs such as saccharide,^[3,4] imidazole,^[5] and guanidinium^[6] groups, the improvement has been limited. As such, enthusiasm for PLL and its modified variants as transfection agents has dwindled. As an alternative, many basic gene delivery studies now utilize a more efficient material such as polyethylenimine (PEI).^[7]

As the use of PLL in gene delivery studies declined, the function of peptide-based materials gradually shifted to other roles relevant to transfection. For example, through covalent conjugation to existing vectors, peptides found use as bioactive agents capable of adding functionality such as cell targeting,^[8,9] nuclear localization,^[10–12] or membrane destabilization^[13] to existing gene delivery materials. Membrane destabilization, in particular, has been a large area for peptide use in nonviral gene delivery systems. The cell-penetrating peptides (CPPs) penetratin,^[14,15] transportan,^[16,17] melittin,^[18–20] GALA,^[21–23] TAT,^[24–26] and oligoarginine^[27–30] are some of the commonly used peptide-based materials for membrane destabilization. When incorporated into delivery vectors, these CPPs have been shown to lead to increased internalization, improved endocytic escape, and overall better

transfection efficiency.^[31] While effective in promoting membrane destabilization as part of a larger vector, CPPs are often too small or lack an adequate cationic charge density to function as stand-alone gene delivery agents.

All cationic polypeptides (PLL, modified PLL, or other polypeptide electrolytes) adopt random coil structures because strong intramolecular charge repulsion between side chains prohibits helix formation.^[32,33] However, a shared feature among many CPPs is a helical secondary structure that allows them to interact with and destabilize lipid bilayers such as the cell and endosomal membranes.^[34,35] Because of this discrepancy in secondary structure, there has been no report of cationic polypeptides that can function as both a gene delivery vector with comparable or better transfection efficiency than some of the leading nonviral delivery vectors, and a CPP that destabilizes cellular membranes.

We recently reported a strategy for the facile generation of cationic and helical polypeptides.^[36] Typically, cationic polypeptides such as PLL are unable to adopt helical conformations at physiological pH because of charge disruption with the side chains.^[32,33] However, our findings revealed that the helical structure of cationic polypeptides can be stabilized by increasing the distance between the charged groups of the side chains and the backbone of the polypeptide, thus minimizing the effect of charge repulsion by reducing the charge density on the helix surface (Scheme 1A). Stable helical structures with very high helical content (> 90 %) can be achieved by maintaining a minimum separation distance of 11 σ bonds between the peptide backbone and the charged side-chain for a polypeptide having completely charged side chains and a reasonable length (degree of polymerization of 60).^[36] By following this general strategy, it is possible to generate polypeptide materials that are sufficiently large and positively charged to bind and condense DNA, but also retain the helical structure seen in many CPPs. The unique combination of material properties allows us to examine helicity as a functional motif in the backbone of gene delivery vectors and evaluate its impact on transfection efficiency.

Herein we report our efforts to develop a library of cationic α -helical polypeptides with CPP-like properties for gene delivery through the well-known ring-opening polymerization (ROP) of amino acid *N*-carboxyanhydrides (NCAs).^[37] The ROP of γ -(4-vinylbenzyl)-L-glutamate *N*-carboxyanhydride (VB-Glu-NCA) was used to form poly(γ -(4-vinylbenzyl)-L-glutamate) (PVBLG; Scheme 1B).^[36,38] PVBLG served as a reactive template that, through subsequent ozonolysis and reductive amination, allowed us to create a library of cationic polypeptides (PVBLG_{*n*}-X, where *n*


[*] Dr. N. P. Gabrielson,^[†] Dr. H. Lu,^[†] Dr. L. Yin, Prof. Dr. J. Cheng
Department of Materials Science and Engineering
University of Illinois, Urbana-Champaign
1304 W. Green Street, Urbana, IL 61801 (USA)
E-mail: jianjunc@illinois.edu
Homepage: <http://cheng.matse.illinois.edu/>

Dr. D. Li, Prof. Dr. F. Wang
Department of Cell and Developmental Biology, University of
Illinois, Urbana-Champaign, Urbana, IL 61801 (USA)
E-mail: feiwang@life.illinois.edu

[†] These authors contributed equally to this work.

[**] J.C. acknowledges support from the NSF (CHE-0809420), the NIH (Director's New Innovator Award 1DP2OD007246, 1R21EB009486 and 1R21A152627), and the Centre for Nanoscale Science and Technology. F.W. acknowledges support from the NIH (GM083812), and NSF (CAREER award 0953267 and EBICS award). N.P.G. acknowledges support from the Institute of Genomic Biology Fellow program, UIUC. H.L. is currently a Jake Wetchler Foundation Fellow for Pediatric Innovation at the Damon Runyon Cancer Research Foundation DRG-2099-11.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201104262>.



Scheme 1. A) Polypeptide with charged side chains and the random coil to helix transformation in response to elongated side chains. B) Reaction Scheme for the synthesis of PVBLG_n-X polypeptides. a) 1. HMDS/TBD/DMF/nitrobenzene; 2. benzyl chloroformate/TBAF/DIPEA, 2 h; b) 1. O₃/CHCl₃, -78 °C, 1-5 min; 2. PPh₃, RT, 2 h; c) 1. RNHR', NaBH(OAc)₃, DMF/HOAc, 60 °C, 24 h; 2. HCl; a) 1. RNHR', DMF/HOAc, 60 °C, 16 h; 2. BH₃ pyridine complex, 8 h; 3. HCl. C) Amine groups used to synthesized PVBLG_n-X. DIPEA = diisopropylethylamine, DMF = N,N'-dimethylformamide, HMDS = hexamethyldisilazide, TBD = 1,5,7-triazabicyclo[4.4.0]dec-5-ene, TBAF = tetra-*n*-butylammonium fluoride.

is the degree of polymerization and X refers to the grafted amine side chain shown in Scheme 1 C). As a result of its glutamate residues, PVBLG has a propensity to adopt an α -helical secondary structure.^[32,33,39,40] By maintaining a minimum separation distance of 11 σ bonds between the peptide backbone and the charged side chains, the PVBLG_n-Xs

synthesized for this study have a helical structure which is stable over a broad range of pH values and salt concentrations, and is also stable when mixed with anionic plasmid DNA (see Figure S1 in the Supporting Information).^[36] By synthesizing and screening a library of materials, we hoped to identify amine side chains that yielded helical molecules with the appropriate balance of hydrophilicity (i.e., DNA binding strength) and hydrophobicity (i.e., endosomolysis) to mimic the membrane-disruptive capabilities of CPPs yet also mediate efficient gene delivery without the addition of extraneous lytic materials.

The synthetic scheme shown in Scheme 1 B was used to generate PVBLG_n-X having 31 different amine side chains. The degree of polymerization was varied between 10 and 300 for the top-performing amines. Of the various side chains, 15 showed improved performance relative to the 22 kDa PLL and two (X = 1 and 8) showed improved performance relative to the 25 kDa branched polyethylenimine (PEI) in COS-7 cells (Figure 1 A). Generally speaking, transfection efficiency increased with increasing molecular weight of PVBLG_n-X. The top-performing material, PVBLG₂₆₇-8, resulted in the highest transfection efficiency—a 12-fold improvement over PEI. The superior performance of PVBLG₂₆₇-8 was confirmed in three additional cell lines (HEK293, MDA-MB-231, and HeLa; see Figure S3a in the Supporting Information). Moreover, in sharp contrast to PEI, PVBLG₂₆₇-8 showed low toxicity in COS-7 cells (Figure 1 B). Circular dichroism analysis (CD) confirmed that PVBLG₂₆₇-8 maintained its helical conformation at physiological pH as well as the acidic pH encountered within endosomes and lysosomes (Figure 1 C).

Since the PVBLG_n-Xs were designed to have an α -helical architecture similar to that found in CPPs, we examined the ability of the polymers to cause pore formation in cell membranes. COS-7 cells were incubated with 250 μ M calcein, a fluorescent dye, in the presence of various concentrations of PVBLG₂₆₇-8. Calcein is unable to cross intact membranes. As such, in the absence of an agent capable of pore formation, calcein is taken up by cells in a pinocytotic fashion, thus resulting in the appearance of small punctate intracellular fluorescent spots (Figure 2 A, 0 μ g mL⁻¹). However, as the amount of PVBLG₂₆₇-8 in the extracellular medium is increased, the intracellular fluorescent signal becomes more diffuse, thus indicating membrane permeation and non-endocytic calcein uptake (Figure 2 A, 50 μ g mL⁻¹). Although PVBLG₂₆₇-8 can function as an effective CPP when present in the medium at 50 μ g mL⁻¹, such a high polypeptide concentration does not correspond with the optimum transfection formulation. Thus, we also tested calcein uptake at an intermediate PVBLG₂₆₇-8 concentration (15 μ g mL⁻¹), which corresponds to the concentration of PVBLG₂₆₇-8 used in the optimum transfection formulation. As indicated by the punctate fluorescent signals, 15 μ g mL⁻¹ PVBLG₂₆₇-8 is unable to cause cell membrane pore formation. Thus, it would seem that the complexes formed between PVBLG₂₆₇-8 and plasmid DNA enter cells by endocytosis and not by direct membrane penetration. This finding is supported by flow cytometry data, which shows reduced complex uptake in the presence of an inhibitor of caveolae-mediated endocytosis




Figure 1. A) In vitro transfection of COS-7 cells with PVBLG_n-X polypeptides. 22 kDa PLL and 25 kDa PEI were included as controls. RLU = relative light units. B) Viability of PVBLG₂₆₇₋₈ and PEI in COS-7 cells. C) CD analysis of PVBLG₂₆₇₋₈ at pH values of 2, 6, and 7.4.

(see Figure S6a in the Supporting Information). Similar results for calcein and complex uptake were observed for analogous experiments conducted in HEK293 cells (Figures S6c and S9).

As PVBLG₂₆₇₋₈ complexes appear to enter cells by endocytosis and not direct membrane transduction, they must escape endocytic vesicles to mediate transfection. PVBLG₂₆₇₋₈ possesses secondary and tertiary amines which can act as buffering agents to aid endosomal escape by the proton sponge effect.^[41] To investigate if this mechanism contributed to the gene delivery observed with PVBLG₂₆₇₋₈, we performed transfections in the presence of bafilomycin A1, an ATPase inhibitor that prevents endosome acidification and thus disrupts the proton sponge effect.^[42] Figure 2B shows that bafilomycin A1 dramatically reduces the gene delivery efficiency of PEI vectors, which are known proton sponges, but has no negative effect on cells transfected with PVBLG₂₆₇₋₈ vectors.^[43] This observation suggests that PVBLG₂₆₇₋₈ escapes from endosomes by membrane disruption. To explore this further, we also performed transfection in the presence of nocodazole. Nocodazole depolymerizes microtubules, thus preventing the active transport of endosomes along their normal progression from early endosomes to late endosomes to lysosomes.^[44] As a result, endocytosed material accumulates in early endosomes. In agreement with

our data indicating that the membrane disruption capabilities of PVBLG₂₆₇₋₈ increase with increasing polymer concentration (Figure 2A), nocodazole causes a greater than twofold increase in the transfection efficiency of PVBLG₂₆₇₋₈ vectors in COS-7 and HEK293 cells (Figure 2B, and see Figure S3b in the Supporting Information). Flow cytometry revealed that this increase was not due to increased complex uptake in drug-treated cells (Figure S6b). Rather, the enhanced transfection in the presence of nocodazole is likely due to the accumulation of PVBLG₂₆₇₋₈ complexes in endocytic vesicles. As more complexes accumulate, the effective polymer concentration becomes large enough to cause enhanced vesicle lysis. Furthermore, confocal microscopy of COS-7 cells treated with nocodazole and transfected with complexes of PVBLG₂₆₇₋₈ and YOYO-labeled DNA showed fluorescent aggregates in the cell cytosol, thus supporting vesicle accumulation (Figure S11).

Our results suggest that secondary structure can have a dramatic impact on the intracellular performance of polymer-based

nonviral gene delivery vehicles. Specifically, the incorporation of helical architecture—a trait shared by many peptides capable of membrane disruption—into our gene delivery vector library yielded polypeptides which possess the ability to disrupt endosomes. Ultimately, this incorporation results in improved transfection performance of the polypeptides relative to random coil polymers like PLL and branched 25 kDa PEI. To directly demonstrate the importance of secondary structure, a random-coil analogue of the top-performing PVBLG_n-8 polymer was synthesized using D- and L- VB-Glu-NCA monomers. The racemic configuration of amino acids (1:1 ratio) was confirmed, by circular dichroism, to prevent the formation of secondary structure in the resulting PVB-DL-G₁₅₀-8 polymer (Figure 2C). For comparison, helical PVB-L-G₁₅₀-8 was also synthesized. Both polymers were used to transfect COS-7 cells over a variety of polymer/DNA weight ratios (Figure 2D). Confirming our speculations from cell penetration and drug inhibition data, the random coil PVB-DL-G₁₅₀-8 polypeptide was unable to mediate effective transfection, whereas the helical PVB-L-G₁₅₀-8 was. This result stands as direct evidence that polymer secondary structure can impact its overall performance.

To test the breadth of applicability of the helical polypeptides as gene delivery vehicles, PVBLG₂₆₇₋₈ was




Figure 2. A) Calcein uptake in COS-7 cells treated with various concentrations of PVBLG₂₆₇₋₈. B) In vitro transfection of COS-7 cells transfected with complexes of 25 kDa PEI or PVBLG₂₆₇₋₈ in the presence of intracellular processing inhibitors. The final PVBLG₂₆₇₋₈ concentration was 10 μg mL⁻¹. C) Circular dichroism spectra of helical PVB-L-G₁₅₀₋₈ and random coil PVB-D,L-G₁₅₀₋₈ in water. d) In vitro transfection of COS-7 cells with PVB-L-G₁₅₀₋₈ and PVB-D,L-G₁₅₀₋₈ polypeptides. 25 kDa PEI was included as a control. E) In vitro transfection of H9 human embryonic stem cells with PVBLG₂₆₇₋₈ in the presence and absence of 10 μM nocodazole and the commercial transfection agent lipofectamine 2000 (LFA).

used to transfect the H9 human embryonic stem cell (hESC) line. hESCs are traditionally hard to transfect, with commercial agents often successfully delivering the transgene to less than 10% of the treated cells.^[45] To explore if the enhanced membrane disruptive properties of PVBLG₂₆₇₋₈ aided transfection in hard-to-transfect cells in addition to cells more amenable to gene delivery (i.e., COS-7 and HEK293 cells), H9 hESCs were transfected with a plasmid coding for green fluorescent protein (pEGFP-N1) and assayed for gene expression 48 hours post-transfection by flow cytometry. As nocodazole treatment was observed to aid transfection with PVBLG₂₆₇₋₈, hESCs were also transfected in the presence and absence of nocodazole (Figure 2E). In addition to PVBLG₂₆₇₋₈, the commercial transfection agent lipofectamine 2000 (LFA) was also evaluated. Without the addition of nocodazole, PVBLG₂₆₇₋₈ at a 20:1 PVBLG₂₆₇₋₈/DNA weight ratio outperforms LFA by 50% and results in approximately 1.5% of all hESCs expressing the transgene. The addition of 10 μM nocodazole to the transfection media increases the percentage of cells successfully transfected with PVBLG₂₆₇₋₈ to roughly 4.5%. This result is approximately a threefold

enhancement over the transfection efficiency of LFA. Microscopy revealed no change in phenotype after either LFA or PVBLG₂₆₇₋₈ transfection, although the addition of nocodazole did result in cell death (see Figure S10 in the Supporting Information).

The study reported here demonstrates the successful application of a library screening approach to the development of α-helical cationic peptides for gene delivery. To our knowledge, this is the first time a library approach has been combined with a reactive template bearing a well-defined and bioactive secondary structure. Our data indicate that certain library members retain the membrane destabilization properties commonly associated with helical peptides yet can also be used to mediate effective gene delivery in a variety of cell lines, including immortalized cancer cells and hESCs. Vector helicity appears to be an essential component in the successful use of polypeptides for gene delivery. In view of the interesting properties of the reported class of helical cationic polypeptides, current studies are focused on developing high throughput strategies to further expand the library as well as exploring the potential for the material to mediate in vivo gene delivery as well as protein and siRNA delivery.

Received: June 20, 2011

Revised: September 19, 2011

Published online: December 7, 2011

Keywords: α-helices · drug delivery · gene delivery · polypeptides · stem cells

- [1] M. Monsigny, A. C. Roche, P. Midoux, R. Mayer, *Adv. Drug Delivery Rev.* **1994**, *14*, 1–24.
- [2] E. Wagner, D. Curiel, M. Cotten, *Adv. Drug Delivery Rev.* **1994**, *14*, 113–135.
- [3] T. Ferkol, J. C. Perales, F. Mularo, R. W. Hanson, *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 101–105.
- [4] P. Erbacher, M. T. Boussier, J. Raimond, M. Monsigny, P. Midoux, A. C. Roche, *Hum. Gene Ther.* **1996**, *7*, 721–729.
- [5] D. Putnam, C. A. Gentry, D. W. Pack, R. Langer, *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 1200–1205.
- [6] T. Okuda, A. Sugiyama, T. Niidome, H. Aoyagi, *Biomaterials* **2004**, *25*, 537–544.
- [7] O. Boussif, F. Lezoualc'h, M. A. Zanta, M. D. Mergny, D. Scherman, B. Demeneix, J. P. Behr, *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 7297–7301.
- [8] K. Kunath, T. Merdan, O. Hegener, H. Häberlein, T. Kissel, *J. Gene Med.* **2003**, *5*, 588–599.
- [9] X. Liu, P. K. Tian, D. W. Ju, M. H. Zhang, M. Yao, X. T. Cao, J. R. Gu, *Cancer Gene Ther.* **2003**, *10*, 529–539.
- [10] R. C. Carlisle, T. Bettinger, M. Ogris, S. Hale, V. Mautner, L. W. Seymour, *Mol. Ther.* **2001**, *4*, 473–583.
- [11] A. Subramanian, P. Ranganathan, S. L. Diamond, *Nat. Biotechnol.* **1999**, *17*, 873–877.
- [12] M. A. Zanta, P. Belguise-Valladier, J. P. Behr, *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 91–96.

- [13] K. Rittner, A. Benavente, A. Bompard-Sorlet, F. Heitz, G. Divita, R. Brasseur, E. Jacobs, *Mol. Ther.* **2002**, *5*, 104–114.
- [14] D. Terrone, S. L. Sang, L. Roudaia, J. R. Silvius, *Biochemistry* **2003**, *42*, 13787–13799.
- [15] D. Derossi, G. Chassaing, A. Prochiantz, *Trends Cell Biol.* **1998**, *8*, 84–87.
- [16] M. Pooga, M. Hällbrink, M. Zorko, U. Langel, *FASEB J.* **1998**, *12*, 67–77.
- [17] M. Pooga, C. Kut, M. Kihlmark, M. Hällbrink, S. Fernaeus, R. Raid, T. Land, E. Hallberg, T. Bartfai, U. Langel, *FASEB J.* **2001**, *15*, 1451–1453.
- [18] M. Ogris, R. C. Carlisle, T. Bettinger, L. W. Seymour, *J. Biol. Chem.* **2001**, *276*, 47550–47555.
- [19] S. Boeckle, J. Fahrmeir, W. Roedl, M. Ogris, E. Wagner, *J. Controlled Release* **2006**, *112*, 240–248.
- [20] C. P. Chen, J. Kim, E. Steenblock, D. Liu, K. G. Rice, *Bioconjugate Chem.* **2006**, *17*, 1057–1062.
- [21] N. K. Subbarao, R. A. Parente, F. C. Szoka, L. Nadasdi, K. Pongracz, *Biochemistry* **1987**, *26*, 2964–2972.
- [22] R. A. Parente, S. Nir, F. C. Szoka, *Biochemistry* **1990**, *29*, 8720–8728.
- [23] W. Li, F. Nicol, F. Szoka, *Adv. Drug Delivery Rev.* **2004**, *56*, 967–985.
- [24] S. Fawell, J. Seery, Y. Daikh, *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 664–668.
- [25] C. Rudolph, C. Plank, J. Lausier, U. Schillinger, R. H. Muller, J. Rosenecker, *J. Biol. Chem.* **2003**, *278*, 11411–11418.
- [26] H. Brooks, B. Lebleu, E. Vives, *Adv. Drug Delivery Rev.* **2005**, *57*, 559–577.
- [27] N. P. Gabrielson, J. Cheng, *Biomaterials* **2010**, *31*, 9117–9127.
- [28] J. S. Choi, K. Nam, J. Y. Park, J. B. Kim, J. K. Lee, J. S. Park, *J. Controlled Release* **2004**, *99*, 445–456.
- [29] T. Kim, J. Baek, J. K. Yoon, J. S. Choi, K. Kim, J. Park, *Bioconjugate Chem.* **2007**, *18*, 309–317.
- [30] S. R. Doyle, C. K. Chan, *Genet. Vaccines Ther.* **2007**, *5*, 11.
- [31] M. E. Martin, K. G. Rice, *AAPS Pharmsci.* **2007**, *9*, E18–E29.
- [32] V. Muñoz, L. Serrano, *Nat. Struct. Biol.* **1994**, *1*, 399–409.
- [33] V. Muñoz, F. J. Blanco, L. Serrano, *Nat. Struct. Biol.* **1995**, *2*, 380–385.
- [34] S. Deshayes, M. C. Morris, G. Divita, F. Heitz, *Cell. Mol. Life Sci.* **2005**, *62*, 1839–1849.
- [35] K. M. Stewart, K. L. Horton, S. O. Kelley, *Org. Biomol. Chem.* **2008**, *6*, 2242–2252.
- [36] H. Lu, J. Wang, Y. Bai, J. W. Lang, S. Liu, Y. Lin, J. Cheng, *Nat. Commun.* **2011**, *2*, 206.
- [37] H. Lu, J. Cheng, *J. Am. Chem. Soc.* **2007**, *129*, 14114–14115.
- [38] H. Lu, Y. Bai, J. Wang, N. P. Gabrielson, F. Wang, Y. Lin, J. Cheng, *Macromolecules* **2011**, *44*, 6237–6240.
- [39] C. N. Pace, J. M. Scholtz, *Biophys. J.* **1998**, *75*, 422–427.
- [40] S. Marqusee, V. H. Robbins, R. L. Baldwin, *Proc. Natl. Acad. Sci. USA* **1989**, *86*, 5286–5290.
- [41] J. P. Behr, *Chimia* **1997**, *51*, 34–36.
- [42] E. J. Bowman, A. Siebers, K. Altendorf, *Proc. Natl. Acad. Sci. USA* **1988**, *85*, 7972–7976.
- [43] A. Akinc, M. Thomas, A. M. Klibanov, R. Langer, *J. Gene Med.* **2005**, *7*, 657–663.
- [44] N. Bayer, D. Schober, E. Prchla, R. F. Murphy, D. Blaas, R. Fuchs, *J. Virol.* **1998**, *72*, 9645–9655.
- [45] J. J. Green, B. Y. Zhou, M. M. Mitalipova, C. Beard, R. Langer, R. Jaenisch, D. G. Anderson, *Nano Lett.* **2008**, *8*, 3126–3130.